


Technology Advisory Committee B Interests Register Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [ID1534b]

Publication Date: 27/10/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Mr Peter Wheatley Price	TAC Committee B Member	Direct - financial	Mr Wheatley Price's employer, Takeda, sells leuprorelin which is used in the hormonal stage of prostate cancer.	NA	14/02/2021	NA	It was agreed that this declaration did not present a conflict of interest and did not prevent Mr Wheatley-Price from participating in this section of the meeting.
Dr Nicholas Latimer	TAC B committee member	Direct financial	Dr Latimer provided advice to Ferring, a comparator company, on the economic modelling for rebyota for clostridium difficile infection in June 2020.	NA	14/06/2021	NA	It was agreed that this declaration did not prevent Dr Latimer from participating in this section of the meeting.
Dr Amit Bahl	Clinical Expert	Direct – financial	Participated in paid advisory boards and received funding for meeting attendance and sponsorship from Sanofi, Astellas, BMS, Janssen, Pfizer, Bayer, EUSA.	NA	09/06/2020	NA	It was agreed that this declaration would not prevent Dr Bahl from providing expert advice to the committee.



Dr Stephen Allen	Patient Expert	Direct – financial	Dr Allen received payment from Janssen, in the form of expenses, for him to attend a patient-centred conference in Europe. No commercial interests were involved.	NA	15/05/2020	NA	It was agreed that this declaration would not prevent Dr Allen from providing expert advice to the committee.
		Indirect interest	Dr Allen's employer, Tackle Prostate Cancer, receives funding from various pharmaceutical companies.	NA	04/03/2021	NA	It was agreed that this declaration would not prevent Dr Allen from providing expert advice to the committee.
Ms Rebecca Leszczynski	Patient Expert	Indirect interest	Ms Leszczynski's employer, Prostate Cancer UK, receives funding from various pharmaceutical companies.	NA	02/12/2020	NA	It was agreed that this declaration would not prevent Ms Leszczynski from providing expert advice to the committee.